中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | AY286014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 설명 |
Anti-Trastuzumab Polyclonal Antibody (AY286014) is a rabbit polyclonal antibody detecting Trastuzumab in ELISA.
Highlights
|
||||||||
| 종 반응성 | General | ||||||||
| 응용 분야 | ELISA | ||||||||
| 숙주 종 | Rabbit | ||||||||
| 클론성 | Polyclonal | ||||||||
| 이소타입 | IgG | ||||||||
| 면역원 | Trastuzumab | ||||||||
| 타겟 | Rabbit polyclonal to Herceptin. | ||||||||
| 특이성 | The product is specific for Trastuzumab. This antibody serves as an excellent positive control for Trastuzumab immunogenicity (ADA) assays. | ||||||||
| 내독소 수준 | Please contact with the lab for this information. | ||||||||
| 순도 | >90% as determined by SDS-PAGE. | ||||||||
| 정제 | Purified by antigen affinity column. | ||||||||
| 등록번호 | CAS: 180288-69-1 | ||||||||
| 형태 | Liquid | ||||||||
| 저장 완충액 | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
||||||||
| 제품 사용 정보 |
| ||||||||
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||||||
| 배경 | Trastuzumab with the brand name Herceptin, is an FDA-approved drug for HER2-targeted therapy for breast cancer. It is a recombinant humanized monoclonal antibody (IgG1 kappa). Trastuzumab binds to HER2 receptor present on the surface of HER2-positive tumour cells and suppresses the cells growth and proliferation. • Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro., PMID:28919583 • Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies., PMID:19393584 • Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines., PMID:32102522 • Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells., PMID:16091755 • Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3)., PMID:19530101 • Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity., PMID:12632061 • IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831., PMID:28533226 • Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer., PMID:11410505 • Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study., PMID:22037080 • Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy., PMID:21255939 | ||||||||
| 참고사항 | For research use only. |
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
